Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00190593 · ClinicalTrials.gov registry record · Phase 3
Raloxifene Use for The Heart
A Phase 3 study of Cardiovascular Diseases and Breast Neoplasms, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 10,000
- Enrollment target
- 1
- Study location
NCT00190593: Completed Phase 3 study of Cardiovascular Diseases and Breast Neoplasms, sponsored by Eli Lilly and Company.
NCT00190593 is a Phase 3 study of Cardiovascular Diseases and Breast Neoplasms that has completed, run by Eli Lilly and Company. The registered enrollment target is 10,000 participants, below the 26,941-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00190593, a Phase 3 study of Cardiovascular Diseases and Breast Neoplasms, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 10,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether raloxifene compared with placebo lowers the risk of coronary events and reduces the risk of invasive breast cancer in postmenopausal women at risk for major coronary events.
Conditions Studied
Interventions
- DRUG placebo
- DRUG raloxifene
Study Locations (1)
Minnesota
- For additonal information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,000 participants |
| Start Date | 1998-06 |
| Est. Completion | 2005-11 |
| Phase | Phase 3 |
What the finished NCT00190593 record still lists
NCT00190593 is an interventional study that assigns participants to a tested intervention. Its 10,000 participants enrollment target places it among the larger protocols in the corpus, below the 26,941-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (63% lower).
The record links to 2 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00190593 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00190593 about?
NCT00190593 is a clinical study titled "Raloxifene Use for The Heart". The purpose of this study is to determine whether raloxifene compared with placebo lowers the risk of coronary events and reduces the risk of invasive breast cancer in postmenopausal women at risk for major coronary events.
What is the current status of trial NCT00190593?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 10,000 participants. The study started on 1998-06. Estimated completion is 2005-11.
What conditions does trial NCT00190593 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Breast Neoplasms.
What interventions are being tested in trial NCT00190593?
The interventions under investigation include: placebo (DRUG), raloxifene (DRUG).
Who is sponsoring clinical trial NCT00190593?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00190593 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00190593's enrollment target sits among peer trials
10,000 14th of 300 higher than 285 of 300 other Cardiovascular Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Behavioral Activation Delivered Via Home-based Telehealth to Improve Functioning in Cardiovascular Disease Patients Recently Discharged From Inpatient Care
RECRUITING · Phase 3
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Cardiovascular Effects of a Healthy Dietary Pattern Containing Eggs
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
ACTIVE NOT RECRUITING · Phase 3
-
Comparison of Hematocrit Levels in Infant Heart Surgery
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00160771 · 10,000 participants
Biomechanics/Motion Analysis Laboratory Data Bank
- NCT00896935 · 10,000 participants
Arizona Cancer Center Biospecimen Repository
- NCT00898235 · 10,000 participants
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
- NCT00992303 · 10,000 participants
Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia